levonorgestrel

Summary

Summary: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.

Top Publications

  1. ncbi Levonorgestrel-releasing intrauterine system: uses and controversies
    Luis Bahamondes
    Department of Obstetrics and Gynecology, School of Medicine, University of Campinas, Caixa Postal 6181, Campinas, SP, Brazil
    Expert Rev Med Devices 5:437-45. 2008
  2. ncbi Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel
    Hans Joachim Ahrendt
    Gynekologická a Porodnická Ambulance, Prague, Czech Republic
    Contraception 80:436-44. 2009
  3. doi Use of the levonorgestrel releasing-intrauterine system in nulliparous women--a non-interventional study in Sweden
    Lena Marions
    Department of Obstetrics and Gynaecology, Division of Women s and Children s Health, Karolinska University Hospital Institutet, Stockholm, Sweden
    Eur J Contracept Reprod Health Care 16:126-34. 2011
  4. pmc Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9
    Øjvind Lidegaard
    Gynaecological Clinic 4232, Rigshospitalet, University of Copenhagen, Denmark
    BMJ 343:d6423. 2011
  5. doi Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system
    Anne Orbo
    Institute of Medical Biology, University of Tromsø, Norway
    Acta Obstet Gynecol Scand 89:1438-46. 2010
  6. ncbi Proteomic analysis of testis biopsies in men treated with injectable testosterone undecanoate alone or in combination with oral levonorgestrel as potential male contraceptive
    Yugui Cui
    Laboratory of Reproductive Medicine, Department of Histology and Embryology, and Center of Clinical Reproductive Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
    J Proteome Res 7:3984-93. 2008
  7. doi Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial
    Andrew M Kaunitz
    Department of Obstetrics and Gynecology, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA
    Obstet Gynecol 116:625-32. 2010
  8. doi Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas
    M Valeria Bahamondes
    Department of Obstetrics and Gynecology, University of Campinas, Campinas, Brazil
    Contraception 84:e11-6. 2011
  9. ncbi Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia
    A Kriplani
    Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
    Int J Gynaecol Obstet 97:190-4. 2007
  10. ncbi transient scrotal hyperthermia and levonorgestrel enhance testosterone-induced spermatogenesis suppression in men through increased germ cell apoptosis
    Christina Wang
    Department of Medicine, Harbor University of California, Los Angeles, Torrance, California 90509, USA
    J Clin Endocrinol Metab 92:3292-304. 2007

Detail Information

Publications234 found, 100 shown here

  1. ncbi Levonorgestrel-releasing intrauterine system: uses and controversies
    Luis Bahamondes
    Department of Obstetrics and Gynecology, School of Medicine, University of Campinas, Caixa Postal 6181, Campinas, SP, Brazil
    Expert Rev Med Devices 5:437-45. 2008
    This article provides a perspective on the use of the levonorgestrel-releasing intrauterine system as a contraceptive method and as therapy in different situations, as well as presenting the corresponding controversies and unresolved ..
  2. ncbi Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel
    Hans Joachim Ahrendt
    Gynekologická a Porodnická Ambulance, Prague, Czech Republic
    Contraception 80:436-44. 2009
    ..E2V/DNG; administered using a dynamic dosing regimen) with a monophasic OC containing ethinyl estradiol 20 mcg/levonorgestrel 100 mcg (EE/LNG). E2V releases estradiol (E2), which is identical to endogenously produced 17beta-estradiol.
  3. doi Use of the levonorgestrel releasing-intrauterine system in nulliparous women--a non-interventional study in Sweden
    Lena Marions
    Department of Obstetrics and Gynaecology, Division of Women s and Children s Health, Karolinska University Hospital Institutet, Stockholm, Sweden
    Eur J Contracept Reprod Health Care 16:126-34. 2011
    To evaluate the insertion procedure and continuation rates of the levonorgestrel releasing-intrauterine system (LNG-IUS) in nulliparous women who, due to fear of complications, are often denied this very effective contraceptive method.
  4. pmc Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9
    Øjvind Lidegaard
    Gynaecological Clinic 4232, Rigshospitalet, University of Copenhagen, Denmark
    BMJ 343:d6423. 2011
    ..To assess the risk of venous thromboembolism from use of combined oral contraceptives according to progestogen type and oestrogen dose...
  5. doi Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system
    Anne Orbo
    Institute of Medical Biology, University of Tromsø, Norway
    Acta Obstet Gynecol Scand 89:1438-46. 2010
    To investigate whether regression of endometrial hyperplasia observed after 3 months of treatment with levonorgestrel impregnated intrauterine system device (LNG-IUS) was sustained after 6 months and whether these effects were still ..
  6. ncbi Proteomic analysis of testis biopsies in men treated with injectable testosterone undecanoate alone or in combination with oral levonorgestrel as potential male contraceptive
    Yugui Cui
    Laboratory of Reproductive Medicine, Department of Histology and Embryology, and Center of Clinical Reproductive Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
    J Proteome Res 7:3984-93. 2008
    Treatment with injectable testosterone undecanoate (TU) alone or in combination with oral levonorgestrel (LNG) resulted in marked decreases in sperm concentrations...
  7. doi Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial
    Andrew M Kaunitz
    Department of Obstetrics and Gynecology, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA
    Obstet Gynecol 116:625-32. 2010
    To compare the efficacy and safety of the levonorgestrel-releasing intrauterine system and oral medroxyprogesterone acetate in the treatment of idiopathic heavy menstrual bleeding.
  8. doi Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas
    M Valeria Bahamondes
    Department of Obstetrics and Gynecology, University of Campinas, Campinas, Brazil
    Contraception 84:e11-6. 2011
    Despite the high contraceptive efficacy and the additional noncontraceptive benefits of the levonorgestrel-releasing intrauterine system (LNG-IUS), concerns persist with respect to its use in nulligravidas...
  9. ncbi Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia
    A Kriplani
    Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
    Int J Gynaecol Obstet 97:190-4. 2007
    To evaluate the efficacy, acceptability, and possible side effects of a levonorgestrel-releasing intrauterine system for menorrhagia.
  10. ncbi transient scrotal hyperthermia and levonorgestrel enhance testosterone-induced spermatogenesis suppression in men through increased germ cell apoptosis
    Christina Wang
    Department of Medicine, Harbor University of California, Los Angeles, Torrance, California 90509, USA
    J Clin Endocrinol Metab 92:3292-304. 2007
    ..In rodents and monkeys, a combination of hormonal and physical agents accelerates germ cell death...
  11. ncbi A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel
    J Endrikat
    Schering AG, Berlin, Germany
    Eur J Contracept Reprod Health Care 7:79-90. 2002
    ..pharmacokinetics of a dose-reduced oral contraceptive containing 20 microg ethinylestradiol (EE) + 100 microg levonorgestrel (LNG) in 18 young, healthy females...
  12. doi The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Am J Obstet Gynecol 204:126.e1-4. 2011
    We sought to assess the effects of long-term use and safety of the levonorgestrel-releasing (LNG)-intrauterine system (IUS) among human immunodeficiency virus (HIV)-infected women in comparison with HIV-infected women not using the device.
  13. ncbi Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women
    Elof Johansson
    Center for Biomedical Research, The Population Council, New York, NY, USA
    Hum Reprod 17:1472-6. 2002
    b>Levonorgestrel (LNG) is a commonly used progestin for emergency contraception; however, little is known about its pharmacokinetics and optimal dose for use.
  14. pmc Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients
    L J Middleton
    Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2TT
    BMJ 341:c3929. 2010
    ..endometrial destruction (both "first generation" hysteroscopic and "second generation" non-hysteroscopic techniques), and the levonorgestrel releasing intrauterine system (Mirena) in the treatment of heavy menstrual bleeding.
  15. ncbi The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease
    F B Lockhat
    Department of Obstetrics and Gynaecology, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK
    Hum Reprod 19:179-84. 2004
    ..A progestogen (levonorgestrel) administered via an intrauterine system (Lng-IUS) has been demonstrated to improve symptoms of endometriosis; ..
  16. ncbi A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception
    Suk Wai Ngai
    Department of Obstetrics and Gynecology, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China
    Hum Reprod 20:307-11. 2005
    b>Levonorgestrel (0.75 mg given for two doses 12 h apart) has been proven to be an effective regimen for emergency contraception when the first dose is given within 72 h of unprotected coitus...
  17. doi Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis
    Anna F Glasier
    National Health Service Lothian, Edinburgh, UK
    Lancet 375:555-62. 2010
    ..We compared the efficacy and safety of ulipristal acetate with levonorgestrel for emergency contraception.
  18. ncbi Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel
    Susan S Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
    Contraception 73:566-70. 2006
    ..have about twice the risk for venous thromboembolism (VTE) compared to users of older OCs containing levonorgestrel. Estimates of the risk for VTE among users of norgestimate-containing OCs compared to other OCs, however, are ..
  19. pmc Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis
    H Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
    BMJ 321:1190-5. 2000
    To compare the risk of idiopathic venous thromboembolism among women taking third generation oral contraceptives (with gestodene or desogestrel) with that among women taking oral contraceptives with levonorgestrel.
  20. pmc Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data
    Susan S Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
    BMJ 342:d2151. 2011
    To compare the risk of non-fatal venous thromboembolism in women receiving oral contraceptives containing drospirenone with that in women receiving oral contraceptives containing levonorgestrel.
  21. doi Expressions of steroid receptors and Ki67 in first-trimester decidua and chorionic villi exposed to levonorgestrel used for emergency contraception
    Chun Xia Meng
    Department of Woman and Child Health, Division of Obstetrics and Gynecology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Fertil Steril 91:1420-3. 2009
    b>Levonorgestrel (1.5 mg) is commonly used for emergency contraception to prevent an unwanted pregnancy after an unprotected intercourse. We found that postovulatory administration of 1...
  22. ncbi A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment
    D Thiboutot
    Division of Dermatology, Pennsylvania State University, Hershey, USA
    Fertil Steril 76:461-8. 2001
    OBJECTIVE: To evaluate the efficacy of a low-dose oral contraceptive (OC) containing 100 microg of levonorgestrel (LNG) and 20 microg of ethinyl estradiol (EE) compared with placebo for the treatment of moderate acne...
  23. doi Intrauterine devices and adolescents
    Melanie A Gold
    Division of Adolescent Medicine, Department of Pediatrics, University of Pittsburgh School of Medicine, PA 15213, USA
    Curr Opin Obstet Gynecol 20:464-9. 2008
    ..The purpose of this review is to inform the reader of new information published on intrauterine devices (IUDs) and adolescents...
  24. ncbi Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis
    L Fedele
    Department of Maternal and Child Health, Biology and Genetics, University of Verona, Verona, Italy
    Fertil Steril 75:485-8. 2001
    To evaluate the effectiveness of a levonorgestrel-releasing IUD as therapy for endometriosis of the rectovaginal septum.
  25. ncbi Pharmacokinetics of levonorgestrel 0.75 mg tablets
    Karin Kook
    Salamandra LLC, Chevy Chase, MD, USA
    Contraception 66:73-6. 2002
    This study examined plasma levonorgestrel (LNG) concentrations and pharmacokinetics following oral administration of a single LNG 0.75 mg tablet. Sixteen healthy female volunteers 19-44 years old enrolled in the study...
  26. ncbi Assessment of menstrual blood loss in Belgian users of the frameless copper-releasing IUD with copper surface area of 200 mm2 and users of a copper-levonorgestrel-releasing intrauterine system
    D Wildemeersch
    Contrel Research, Ghent, Belgium
    Contraception 70:169-72. 2004
    This study was conducted to evaluate the effect of a miniaturized frameless copper IUD (GyneFix 200 small) and a copper-levonorgestrel (GynePlant) intrauterine system (IUS) on the amount of menstrual blood loss (MBL).
  27. doi Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue
    Yesim Bayoglu Tekin
    Department of Obstetric and Gynecology, Agri Patnos Public Hospital, Ministry of Health, Patnos Agri, Turkey
    Fertil Steril 95:492-6. 2011
    To compare efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena) with depot GnRH analogue (GnRH-a; gosareline acetate; Zoladex) on endometriosis-related chronic pelvic pain (CPP) in patients with severe ..
  28. doi Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system
    Takeshi Maruo
    Kobe Children s Hospital and Feto Mternal Medical Center, Kobe 654 0081, Japan
    Contraception 82:435-41. 2010
    The use of levonorgestrel-releasing intrauterine system (LNG-IUS) is effective for management of menorrhagic women with uterine myomas because of reduction in menorrhagia...
  29. doi Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis
    Ioannis D Gallos
    Academic Unit of Obstetrics and Gynaecology, Birmingham Women s Hospital, Birmingham, UK
    Am J Obstet Gynecol 203:547.e1-10. 2010
    To conduct a systematic review and metaanalysis of studies evaluating the regression rate of endometrial hyperplasia with oral progestogens and levonorgestrel-releasing intrauterine system.
  30. ncbi The effects of levonorgestrel on various sperm functions
    William S B Yeung
    Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong, China
    Contraception 66:453-7. 2002
    Two doses of 750-microg levonorgestrel at 12 h apart is one of the regimens for emergency contraception. The mechanism of action of this regimen is not fully known...
  31. ncbi Levonorgestrel-releasing intrauterine system vs. endometrial thermal ablation for menorrhagia
    Theodoros D Theodoridis
    1st Department of Obstetrics and Gynaecology, Papageorgiou General Hospital, Aristotle University of Thessaloniki, Periferiaki Odos Thessalonikis, N Efkarpia, Thessaloniki, Greece
    Hormones (Athens) 8:60-4. 2009
    To evaluate the efficacy of a Levonorgestrel-releasing Intrauterine System (LNG-IUS) in controlling menorrhagia in comparison with endometrial thermal rollerball ablation.
  32. ncbi Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men
    You lun Gui
    Shanghai Institute of Planned Parenthood Research, 2140 Xie Tu Rd, Shanghai 200032, China
    J Androl 25:720-7. 2004
    ..degrees of sperm suppression in white men, we hypothesized that the combination of TU and the progestin levonorgestrel (LNG) would result in improved spermatogenic suppression in Chinese men...
  33. ncbi Use of three-dimensional ultrasound in evaluating the intrauterine position of a levonorgestrel-releasing intrauterine system
    Efraim Zohav
    Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, 78278, Israel
    Reprod Biomed Online 14:495-7. 2007
    ..reports the first case of three-dimensional (3-D) transvaginal ultrasonography (TVS) imaging of malpositioned levonorgestrel-releasing intrauterine system (LNG-IUS)...
  34. ncbi The in vitro effect of levonorgestrel on the acrosome reaction of human spermatozoa from fertile men
    L Bahamondes
    Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas UNICAMP, Caixa Postal 6181, 13084 971, Campinas, Sao Paulo, Brazil
    Contraception 68:55-9. 2003
    The objective of the study was to evaluate the effect of levonorgestrel (LNG) on the occurrence of acrosome reaction (AR) of capacitated spermatozoa from fertile men. A total of 20 semen samples from four fertile men were evaluated...
  35. ncbi A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception
    H Hamoda
    Department of Obstetrics and Gynaecology, University of Aberdeen, United Kingdom
    Obstet Gynecol 104:1307-13. 2004
    To compare the efficacy, patient acceptability and adverse effects of low-dose mifepristone (10 mg) with the levonorgestrel regimen (2 doses of 750 microg given 12 hours apart) for emergency contraception.
  36. ncbi Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection
    Ilkka Rauramo
    The Finnish Medical Society Duodecim, Helsinki, Finland
    Obstet Gynecol 104:1314-21. 2004
    The purpose of this study was to compare the long-term efficacy of the levonorgestrel intrauterine system and transcervical resection of the endometrium in the treatment of menorrhagia.
  37. ncbi Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device
    Sergio Haimovich
    Department of Obstetrics and Gynecology, Hospital Universitari del Mar, Autonomous University of Barcelona, Barcelona, Spain
    Menopause 15:1002-4. 2008
    To assess the effectiveness of the Mirena levonorgestrel-releasing intrauterine system (LNG-IUS) in peri- and postmenopausal women with endometrial hyperplasia without atypia.
  38. pmc Practice tips. Inserting the levonorgestrel intrauterine system: off-label use
    Catherine Caron
    Department of Family Medicine, University of Ottawa, Ontario
    Can Fam Physician 53:643-4. 2007
  39. ncbi The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia
    S C L Koh
    Department of Obstetrics and Gynaecology, National University of Singapore, Yong Loo Lin School of Medicine, National University Hospital, Singapore, Singapore
    J Thromb Haemost 5:133-8. 2007
    ..The levonorgestrel-releasing intrauterine system (LNG-IUS) ranks higher than medical treatments in terms of efficacy, comparable ..
  40. ncbi Therapeutic levels of levonorgestrel detected in blood plasma of fish: results from screening rainbow trout exposed to treated sewage effluents
    Jerker Fick
    Department of Chemistry, Umea University, Umea, Sweden
    Environ Sci Technol 44:2661-6. 2010
    ..The progestin pharmaceutical levonorgestrel was detected in fish blood plasma at concentrations (8...
  41. ncbi The in vitro effect of emergency contraception doses of levonorgestrel on the acrosome reaction of human spermatozoa
    Karen Saboya Brito
    Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas UNICAMP, 13084 971 Campinas, Brazil
    Contraception 72:225-8. 2005
    The aim of this study was to evaluate the effect of three concentrations of levonorgestrel (LNG) comparable to the levels found in serum following ingestion of LNG as emergency contraception (EC) on the acrosome reaction (AR) of ..
  42. ncbi A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms
    K Halmesmäki
    Department of Obstetrics and Gynecology, Central Hospital of Päijät Häme, Keskussairaalankatu 7, 15850 Lahti, Finland
    Hum Reprod 19:378-82. 2004
    The purpose of this study was to compare the effects of hysterectomy and a levonorgestrel-releasing intrauterine system (LNG-IUS) on serum FSH levels and menopausal symptoms.
  43. doi Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system
    Paul D Blumenthal
    Department of Obstetrics and Gynecology, Stanford University, Stanford, USA
    Int J Gynaecol Obstet 112:171-8. 2011
    To review the literature for economic and health-related quality of life outcomes data associated with the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) in the management of heavy menstrual bleeding.
  44. doi Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006)
    Taek Sang Lee
    Department of Obstetrics and Gynecology, Gangnam CHA Medical Center, CHA University, 650 9, Yoksam Dong, Gangnam Gu, Seoul 135 913, Republic of Korea
    Jpn J Clin Oncol 41:817-9. 2011
    A prospective multicenter trial has been commenced in Korea to investigate the treatment efficacy of the levonorgestrel-releasing intrauterine system in patients with endometrial hyperplasia...
  45. pmc Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database
    Lianne Parkin
    Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, New Zealand
    BMJ 342:d2139. 2011
    To examine the risk of non-fatal idiopathic venous thromboembolism in current users of a combined oral contraceptive containing drospirenone, relative to current users of preparations containing levonorgestrel.
  46. ncbi Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis
    S Hennessy
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Contraception 64:125-33. 2001
    ..and gestodene are associated with an increased risk of venous thromboembolism (VTE) versus OCs containing levonorgestrel. We were interested in synthesizing the available data, exploring explanations for mixed results, and ..
  47. ncbi The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review
    Andrew M Kaunitz
    Department of Obstetrics and Gynecology, University of Florida College of Medicine Jacksonville, FL 32209, USA
    Drugs 72:193-215. 2012
    ..databases to evaluate the clinical evidence and provide an update on the risks and benefits of using the levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of HMB...
  48. doi The cost-effectiveness of the levonorgestrel-releasing intrauterine system for the treatment of idiopathic heavy menstrual bleeding in the United States
    Michael L Ganz
    United BioSource Corporation, Lexington, MA 02420, USA
    Value Health 16:325-33. 2013
    ..Our objective was to evaluate the cost-effectiveness of the levonorgestrel-releasing intrauterine system (LNG-IUS) compared with other therapies for idiopathic heavy menstrual bleeding.
  49. ncbi Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization
    O Meirik
    United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)/World Health Organization (WHO)/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Geneva, Switzerland
    Obstet Gynecol 97:539-47. 2001
    OBJECTIVE: To evaluate safety and efficacy of levonorgestrel-releasing contraceptive implants (Norplant; Leiras Oy, Turku, Finland) in developing countries. METHODS: We used controlled cohort methodology...
  50. pmc Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel
    Christine Klipping
    Dinox BV, Groningen, The Netherlands
    Drugs R D 11:159-70. 2011
    ..Based on previous studies, it is expected that this estradiol-based COC will have a reduced hepatic effect compared with COCs containing ethinylestradiol with regard to proteins controlling the hemostatic balance...
  51. ncbi Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia
    Zeina J Haoula
    Department of Obstetrics and Gynaecology, University Hospital, Queens Medical Centre, Nottingham, NG7 2UH, United Kingdom
    Eur J Obstet Gynecol Reprod Biol 159:176-9. 2011
    The objective of this study was to evaluate the potential treatment of atypical and non-atypical endometrial hyperplasia with the levonorgestrel intrauterine system (LNG-IUS).
  52. ncbi Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia
    B Chattopdhyay
    Department of Obstetrics and Gynaecology, Lady Hardinge Medical College, New Delhi, India
    Eur Rev Med Pharmacol Sci 15:764-8. 2011
    To evaluate the efficacy, acceptability and side effects of levonorgestrel intrauterine system in patients with idiopathic menorrhagia.
  53. ncbi A biodegradable levonorgestrel-releasing implant made of PCL/F68 compound as tested in rats and dogs
    Guilei Ma
    The Tianjin Key Laboratory of Biomaterials, Institute of Biomedical Engineering, Peking Union Medical College and Chinese Academy of Medical Sciences, Nankai District, Tianjin 300192, China
    Contraception 74:141-7. 2006
    ..Our objective was to report preclinical studies on a biodegradable long-acting contraceptive implant...
  54. doi Ibuprofen prophylaxis for levonorgestrel-releasing intrauterine system insertion: a randomized controlled trial
    Julie Chor
    Department of Obstetrics and Gynecology, John H Stroger Jr Hospital of Cook County, Chicago, IL 60612, USA
    Contraception 85:558-62. 2012
    Despite the high efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) in preventing pregnancy, uptake of the intrauterine devices remains low in the United States...
  55. ncbi Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users
    E Marbaix
    Christian de Duve Institute of Cellular Pathology, Department of Pathology, Medical School of the Université catholique de Louvain, Bruxelles, Belgium
    Hum Reprod 15:120-34. 2000
    Unpredictable endometrial bleeding is the major side-effect of levonorgestrel-releasing s.c. implants (Norplant), otherwise a method of choice for long-term contraception...
  56. doi The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia
    Jan Endrikat
    Bayer HealthCare, Berlin, Germany
    Arch Gynecol Obstet 285:117-21. 2012
    Idiopathic menorrhagia (IM) is an important clinical challenge. The levonorgestrel-releasing intrauterine system (LNG IUS) provides an effective treatment option as shown by multiple small clinical studies...
  57. ncbi Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII
    Marianne van Rooijen
    Department of Woman and Child Health, Division of Obstetrics and Gynaecology, King Gustaf V Research Institute, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    Am J Obstet Gynecol 186:44-8. 2002
    ..The objective of the study was to compare the effects of two different combined oral contraceptives on levels of plasma lipoproteins and coagulation factor VII...
  58. doi The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception
    Diana Mansour
    New Croft Centre, NE1 6ND Newcastle upon Tyne, UK
    Contraception 85:224-34. 2012
    The contraceptive profile of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena®) is well established, with efficacy similar to that achieved with sterilization and rapid return to fertility after discontinuation of use...
  59. pmc Proultraflexible lipid vesicles for effective transdermal delivery of levonorgestrel: development, characterization, and performance evaluation
    Subheet Jain
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India
    AAPS PharmSciTech 6:E513-22. 2005
    ..of new vesicular drug carrier system protransfersomes for transdermal delivery of the contraceptive agent, levonorgestrel. Protransfersome gel (PTG) formulations of levonorgestrel were prepared and characterized for vesicle shape, ..
  60. doi The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding
    George A Vilos
    St Joseph s Health Care, Department of Obstetrics and Gynecology, The University of Western Ontario, London, Ontaio, Canada
    J Minim Invasive Gynecol 18:75-80. 2011
    To evaluate the use of the levonorgestrel intrauterine system (LNG-IUS) in obese premenopausal women with abnormal uterine bleeding (AUB).
  61. ncbi [Effects of levonorgestrel-releasing intrauterine system on pain and recurrence associated with endometriosis and adenomyosis]
    Shan Deng
    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
    Zhonghua Fu Chan Ke Za Zhi 41:664-8. 2006
    To observe the effects of levonorgestrel-releasing intrauterine system (LNG-IUS) in treatment of pain associated with endometriosis (EM) and adenomyosis (AM), and in prevention of disease recurrence.
  62. doi Levonorgestrel intrauterine system versus medical therapy for menorrhagia
    Janesh Gupta
    School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom
    N Engl J Med 368:128-37. 2013
    ..In a pragmatic, multicenter, randomized trial, we compared the levonorgestrel-releasing intrauterine system (levonorgestrel-IUS) with usual medical treatment in women with menorrhagia who ..
  63. ncbi Effect of mifepristone and levonorgestrel on expression of steroid receptors in the human Fallopian tube
    A Christow
    Division of Obstetrics and Gynecology, Department of Woman and Child Health, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Mol Hum Reprod 8:333-40. 2002
    It is likely that mifepristone or levonorgestrel in the future will find extended use for contraceptive purposes. It is therefore essential to characterize the modes of action of these compounds...
  64. ncbi The synthetic progestogen, Levonorgestrel, but not natural progesterone, affects male mate calling behavior of Xenopus laevis
    Frauke Hoffmann
    Department of Ecophysiology and Aquaculture, Leibniz Institute of Freshwater Ecology and Inland Fisheries, Berlin, Germany
    Gen Comp Endocrinol 176:385-90. 2012
    ..to three environmentally relevant concentrations (10(-7) M, 10(-8) M and 10(-10) M) of the synthetic progestin Levonorgestrel (LNG) and the corresponding natural steroid progesterone (PRG), respectively...
  65. doi The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device
    Astrid van Hylckama Vlieg
    Department of Clinical Epidemiology, Leiden University Medical Center, C7 P, PO Box 9600, NL 2300 RC Leiden, The Netherlands
    Arterioscler Thromb Vasc Biol 30:2297-300. 2010
    ..of venous thrombosis associated with nonoral contraceptives (ie, injectable depot-medroxyprogesterone acetate contraceptives, hormone [levonorgestrel]-releasing intrauterine devices, a contraceptive patch, or a contraceptive implant).
  66. doi Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial
    Prasong Tanmahasamut
    Gynecologic Endocrinology Unit, Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Obstet Gynecol 119:519-26. 2012
    To estimate the effectiveness of a postoperative levonorgestrel-releasing intrauterine system for relieving pelvic pain in patients with endometriosis.
  67. doi Efficacy of levonorgestrel intrauterine system (LNG-IUS) for abnormal uterine bleeding and contraception
    Nabia Tariq
    Department of Obstetrics and Gynaecology, Shifa College of Medicine, Islamabad
    J Coll Physicians Surg Pak 21:210-3. 2011
    To find out clinical response, side effects and patients' acceptability of levonorgestrel-releasing intrauterine system (LNG-IUS).
  68. ncbi The pharmacokinetics of 750 microg levonorgestrel following administration of one single dose or two doses at 12- or 24-h interval
    D Tremblay
    Laboratoire HRA Pharma, 19, , 75020 Paris, France
    Contraception 64:327-31. 2001
    The administration of two tablets of 750 microg levonorgestrel at a 12- to 24-h interval has been shown to be a safe and effective means of emergency contraception, and Norlevo/Vikela (N/V) is a dedicated product for this indication...
  69. doi The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study
    Alexandr I Pashov
    Department of Obstetrics and Gynecology, State Medical University n a V F Voyno Yasenetsky, Krasnoyarsk, Russia
    Gynecol Endocrinol 28:559-61. 2012
    ..After the third injection of 3.75 mg of leuproreline acetate, the levonorgestrel intrauterine hormonal system containing 52 mg levonorgestrel (Mirena®, Bayer, Germany) was inserted for at ..
  70. ncbi Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception
    K Gemzell-Danielsson
    Department of Woman and Child Health, Division of Obstetrics and Gynecology, Karolinska Hospital Institute, S 171 76 Stockholm, Sweden
    Hum Reprod Update 10:341-8. 2004
    ..Recently, treatment with either 10 mg mifepristone or 1.5 mg of levonorgestrel has emerged as the most effective hormonal method for emergency contraception with very low side-effects...
  71. doi Levonorgestrel administration in emergency contraception: bleeding pattern and pituitary-ovarian function
    Alessandra Tirelli
    Department of Obstetrics, Gynecology and Pediatrics Sciences, Obstetrics and Gynecology Unit, Policlinico of Modena, Via del Pozzo 71, Modena, Italy
    Contraception 77:328-32. 2008
    This study was conducted to evaluate the effects of levonorgestrel administration for emergency contraception (EC) on bleeding pattern and pituitary-ovarian function.
  72. pmc Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers
    Samantha Abel
    Pfizer Global R and D, Sandwich, UK
    Br J Clin Pharmacol 65:19-26. 2008
    ..on the pharmacokinetics of midazolam, a sensitive probe CYP3A4 substrate; lamivudine/zidovudine, a combination of nucleoside reverse transcriptase inhibitors (NRTIs); and ethinyloestradiol/levonorgestrel, a combination oral contraceptive.
  73. ncbi Levonorgestrel-only dosing strategies for emergency contraception
    Laura B Hansen
    Department of Clinical Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, Colorado 80262 0238, USA
    Pharmacotherapy 27:278-84. 2007
    ..States Food and Drug Administration-approved progestin-only dosing strategy for emergency contraception is levonorgestrel 0.75 mg taken as soon as possible within 72 hours of unprotected intercourse, with a second 0...
  74. ncbi Bleeding patterns after use of levonorgestrel emergency contraceptive pills
    Elizabeth G Raymond
    Family Health International, PO Box 13950, Research Triangle Park, NC 27709, USA
    Contraception 73:376-81. 2006
    The objective of this study was to describe bleeding after use of an emergency contraceptive pill (ECP) regimen consisting of 1.5 mg of levonorgestrel in a single dose.
  75. pmc Effect of a single vaginal administration of levonorgestrel in Carraguard gel on the ovulatory process: a potential candidate for "dual protection" emergency contraception
    Vivian Brache
    PROFAMILIA, Biomedical Research Department, P O Box 1053, Santo Domingo 10401, Dominican Republic
    Contraception 76:111-6. 2007
    The study was conducted to evaluate the effect of Carraguard vaginal gel containing 0.75 mg of levonorgestrel (CARRA/LNG gel) administered in a single dose at different stages of follicle development over subsequent follicle rupture and ..
  76. pmc Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraception
    Regine Sitruk-Ware
    Population Council, Center for Biomedical Research, New York, NY 10021, USA
    Contraception 75:454-60. 2007
    The study was conducted to assess levonorgestrel (LNG) serum levels achieved after a single administration of two different doses of Carraguard vaginal gel containing LNG (CARRA/LNG), designed for use as microbicide and contraceptive for ..
  77. ncbi Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route
    Luigi Devoto
    Instituto de Investigaciones Materno Infantil, Departamento de Obstetricia y Ginecologia, Medical Faculty, Hospital San Borja Arriaran, University of Chile, Santiago, Chile
    Fertil Steril 84:46-51. 2005
    To determine the pharmacokinetics and endometrial tissue levels of levonorgestrel when taken as a single dose of 1.5 mg either orally or vaginally by healthy women in the periovulatory phase of their menstrual cycle.
  78. ncbi Short term suppression of follicular recruitment and spontaneous ovulation in the cat using levonorgestrel versus a GnRH antagonist
    K M Pelican
    Department of Reproductive Sciences, Conservation and Research Center, Smithsonian s National Zoological Park, Front Royal, VA 22630, USA
    Gen Comp Endocrinol 144:110-21. 2005
    Suppression and subsequent rebound of ovarian activity using a progestin (levonorgestrel; Norplant) versus a GnRH antagonist (antide) was assessed in the domestic cat via fecal estradiol and progesterone metabolite analyses...
  79. ncbi Benefit-risk assessment of the levonorgestrel intrauterine system in contraception
    Tiina Backman
    Department of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland
    Drug Saf 27:1185-204. 2004
    The levonorgestrel-releasing intrauterine system (IUS) is a long-acting, fully reversible method of contraception...
  80. ncbi Determination of levonorgestrel in human plasma by liquid chromatography-tandem mass spectrometry method: application to a bioequivalence study of two formulations in healthy volunteers
    Li zi Zhao
    School of Pharmaceutical Sciences, Sun Yat Sen University, 74 Zhongshan Road II, and Department of Pharmacy the First Affiliated Hospital, Guangzhou 510080, People s Republic of China
    Biomed Chromatogr 22:519-26. 2008
    A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to determine levonorgestrel in human plasma was developed and fully validated...
  81. ncbi A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel
    Sven O Skouby
    Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, DK 2000 Copenhagen F, Denmark
    Contraception 71:111-7. 2005
    To evaluate the impact on lipid and carbohydrate variables of a combined one-third ethinyl estradiol (EE)/levonorgestrel (LNG) dose reduction in oral contraceptives.
  82. ncbi Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians
    A O Arowojolu
    Fertility Research Unit, Obstetrics and Gynaecology Department, University College Hospital, Ibadan, Nigeria
    Contraception 66:269-73. 2002
    ..To find an acceptable levonorgestrel regimen for emergency contraception in our community, the two-dose regimen 0...
  83. doi Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism
    Susan S Jick
    Boston Collaborative Drug Surveillance Program, Department of Epidemiology, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA
    Contraception 81:16-21. 2010
    ..Concern has been raised that the risk of venous thromboembolism (VTE) in users of the ORTHO EVRA patch is higher compared to users of oral contraceptives (OCs)...
  84. ncbi Intrauterine contraceptives: a review of uses, side effects, and candidates
    Noa a Shimoni
    Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, New York 10032, USA
    Semin Reprod Med 28:118-25. 2010
    ..Pomona, NY), and the levonorgestrel-releasing intrauterine system (LNG-IUS), marketed as Mirena (Bayer HealthCare Pharmaceuticals, Inc...
  85. doi Effects of oral and vaginal administration of levonorgestrel emergency contraception on markers of endometrial receptivity
    C X Meng
    Division of Obstetrics and Gynaecology, Department of Women s and Children s Health, Karolinska University Hospital Karolinska Institutet, SE 17176 Stockholm, Sweden
    Hum Reprod 25:874-83. 2010
    The standard regimen of the levonorgestrel-only pill (1.5 mg either in a single dose or in a dose of 0...
  86. doi A randomized prospective trial comparing the levonorgestrel-releasing intrauterine system with thermal balloon ablation for the treatment of heavy menstrual bleeding
    Sérgio S de Souza
    Professor Aroldo Fernando Camargos Laboratory of Human Reproduction, Teaching Hospital of the Federal University of Minas Gerais, Minas Gerais, Brazil
    Contraception 81:226-31. 2010
    Use of the levonorgestrel-releasing intrauterine system (LNG-IUS) was compared with thermal balloon ablation (TBA) for the treatment of heavy menstrual bleeding (HMB).
  87. ncbi Protease activated receptor-1 is down regulated by levonorgestrel in endometrial stromal cells
    S Hague
    Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Angiogenesis 5:93-8. 2002
    ..The use of intrauterine levonorgestrel (LNG) is however, associated with endometrial atrophy and decidualisation of the stroma...
  88. ncbi An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables
    Jan Endrikat
    Schering AG, Mullerstrasse 178, D 13342 Berlin, Germany
    Contraception 65:215-21. 2002
    ..the influence of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol (EE) and 100 microg levonorgestrel (20 EE) with a reference preparation containing 30 microg EE and 150 microg levonorgestrel (30 EE) on ..
  89. doi A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia
    Gamal H Sayed
    Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt
    Int J Gynaecol Obstet 112:126-30. 2011
    To compare the efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) with that of a low-dose combined oral contraceptive (COC) in reducing fibroid-related menorrhagia.
  90. doi Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation
    Gabriela Noe
    Instituto Chileno de Medicina Reproductiva ICMER, Santiago, Chile
    Contraception 81:414-20. 2010
    We aimed to evaluate whether emergency contraception with levonorgestrel (LNG-EC) administered after ovulation is equally effective to LNG-EC administered before ovulation.
  91. doi Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial
    Mamdouh M Shaaban
    Faculty of Medicine, Department of Obstetrics and Gynecology, Assiut University, Assiut 71526, Egypt
    Contraception 83:48-54. 2011
    This study compared the efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) to low dose combined oral contraceptive pills (COC) in the management of idiopathic menorrhagia.
  92. ncbi Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection
    O Istre
    Department of Obstetrics and Gynecology, Central Hospital of Hedmark County, Hamar, Norway
    Fertil Steril 76:304-9. 2001
    Treatment of menorrhagia with levonorgestrel intrauterine system (LNG IUS) and transcervical resection.
  93. ncbi Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Contraception 81:481-6. 2010
    ..Misoprostol has been studied intensively to produce cervical dilatation. To date, no studies have evaluated the effectiveness, safety or acceptability of this treatment for repeat intrauterine device insertions...
  94. ncbi Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study
    Jürgen Dinger
    Director, ZEG Berlin Center for Epidemiology and Health Research, Invalidenstrasse 115, 10115 Berlin, Germany
    J Fam Plann Reprod Health Care 36:123-9. 2010
    ..e. containing < or =30 microg EE), particularly oral contraceptives containing levonorgestrel (LNG)...
  95. doi A single midcycle dose of levonorgestrel similar to emergency contraceptive does not alter the expression of the L-selectin ligand or molecular markers of endometrial receptivity
    Wilder Alberto Palomino
    Instituto de Investigaciones Materno Infantil, Universidad de Chile, Santiago de Chile, Chile
    Fertil Steril 94:1589-94. 2010
    To examine the effects of a single-dose of 1.5 mg of levonorgestrel (commonly used as emergency contraceptive) on endometrial receptivity biomarkers through the oral or vaginal route.
  96. ncbi Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes
    Mehmet Murat Naki
    Obstetrics and Gynecology Department, Dr Lutfi Kirdar Kartal Research and Training Hospital, Kartal, Istanbul, Turkey
    Fertil Steril 94:371-4. 2010
    b>Levonorgestrel- (LNG) releasing intrauterine device (IUD) insertion revealed significant reduction in visual bleeding scores and spotting with an increase in amenorrhea and uterine pulsatility index scores...
  97. ncbi A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia
    Jan Endrikat
    Bayer Inc, Toronto, Ontario, Canada
    J Obstet Gynaecol Can 31:340-7. 2009
    To evaluate the efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) compared with a combined oral contraceptive containing 1 mg norethindrone acetate and 20 mg ethinyl estradiol (OC1/20) in reducing menstrual blood loss (..
  98. pmc Development of an animal experimental model to study the effects of levonorgestrel on the human endometrium
    M L Alvarez Gonzalez
    Laboratory of Tumor and Development Biology, GIGA Research, B23, University de Liège, Sart Tilman, B 4000 Liege, Belgium
    Hum Reprod 24:697-704. 2009
    ..This study was designed to develop an animal model to test the response of endometrium to local progestin delivery...
  99. ncbi Nasal delivery of levonorgestrel for contraception: an experimental study in rats
    Aliasgar Shahiwala
    Pharmacy Department, Faculty of Technology and Engineering, M S University of Baroda, Kalabhavan, Vadodara 390 001, Gujarat, India
    Fertil Steril 81:893-8. 2004
    To ascertain the nasal bioavailability of Levonorgestrel and change formulation components to provide long-term effective concentrations of the drug in blood...
  100. doi Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant
    Shumei Zhao
    Department of Obstetrics and Gynecology, CONRAD Clinical Research Center, Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Contraception 79:469-78. 2009
    Endometrial spotting and/or bleeding (ESB) occurs in levonorgestrel subcutaneous implant (LNG SI) users. Matrix metalloproteinases (MMPs) may play a role in ESB.
  101. doi The Femilis LNG-IUS: contraceptive performance-an interim analysis
    Dirk Wildemeersch
    Outpatient Gynaecological Clinic and Training Centre, Ghent, Belgium
    Eur J Contracept Reprod Health Care 14:103-10. 2009
    To provide an update on the experience with the Femilis levonorgestrel-releasing intrauterine system (LNG-IUS) used for up to five years by parous and nulliparous women, particularly with regard to its contraceptive performance.

Research Grants73

  1. ENDOMETRIAL VEGF: ENDOCRINE REGULATION OF ANGIOGENESIS
    Robert Taylor; Fiscal Year: 1999
    ..underly irregular bleeding commonly associated with depot medroxyprogesterone acetate (DMPA) injections and levonorgestrel- containing silastic capsules (Norplant)...
  2. Industrial Hygieve Training Program-Core
    Stephen Reynolds; Fiscal Year: 2005
    ..The I.H. Program is ABET-accredited as an Applied Science program in Industrial Hygiene. Since its inception in 1975, the program has graduated more than 180 students. ..
  3. EC Method: Determinants for Copper IUD Use and Future Unintended Pregnancy
    David Turok; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Widely available oral levonorgestrel for emergency contraception (EC) has not reduced unplanned pregnancy rates...
  4. POSTMENOPAUSAL ESTROGENS AND ATHEROSCLEROSIS
    Frank Sacks; Fiscal Year: 1992
    ..2) Progestins. Androgenic progestins, such as levonorgestrel, are used in oral contraceptives and with estrogen in postmenopausal hormonal replacement...
  5. A pharmacokinetic evaluation of levonorgestrel implant and antiretroviral therapy
    Kimberly K Scarsi; Fiscal Year: 2012
    ..gap in knowledge, the overall aim of this proposal i to conduct a PK study to evaluate the combination of a levonorgestrel (LNG) implant and NNRTI (nevirapine or efavirenz)-based ART in HIV-infected Ugandan women...
  6. RCT of LNG-IUD vs. DMPA for young postpartum women
    Nancy Stanwood; Fiscal Year: 2004
    ..The levonorgestrel intrauterine device (LNG-IUD) is a very effective, well-tolerated contraceptive...
  7. A RCT of LNG-IUD vs. DMPA for young postpartum women
    Nancy Stanwood; Fiscal Year: 2005
    ..The levonorgestrel intrauterine device (LNG-IUD) is a very effective, well-tolerated contraceptive...
  8. Family Planning Promotion in HIV Infected Zambians
    Susan Allen; Fiscal Year: 2004
    ..Cost- effectiveness will be determined with methods developed jointly by experts in the fields of HIV therapy in Africa and contraception. ..
  9. Family Planning Promotion in HIV Infected Zambians
    Susan Allen; Fiscal Year: 2002
    ..Cost- effectiveness will be determined with methods developed jointly by experts in the fields of HIV therapy in Africa and contraception. ..
  10. Family Planning Promotion in HIV Infected Zambians
    Susan Allen; Fiscal Year: 2005
    ..Cost- effectiveness will be determined with methods developed jointly by experts in the fields of HIV therapy in Africa and contraception. ..
  11. Family Planning Promotion in HIV Infected Zambians
    Susan Allen; Fiscal Year: 2005
    ..Cost- effectiveness will be determined with methods developed jointly by experts in the fields of HIV therapy in Africa and contraception. ..
  12. Family Planning Promotion in HIV Infected Zambians
    Susan Allen; Fiscal Year: 2003
    ..Cost- effectiveness will be determined with methods developed jointly by experts in the fields of HIV therapy in Africa and contraception. ..
  13. Family Planning Promotion in HIV Infected Zambians
    Susan Allen; Fiscal Year: 2004
    ..Cost- effectiveness will be determined with methods developed jointly by experts in the fields of HIV therapy in Africa and contraception. ..
  14. Family Planning Promotion in HIV Infected Zambians
    Susan Allen; Fiscal Year: 2001
    ..Cost- effectiveness will be determined with methods developed jointly by experts in the fields of HIV therapy in Africa and contraception. ..
  15. UNDERSTANDING OVARIAN CONTROL IN RARE BIOMEDICAL MODELS
    KATHARINE PELICAN; Fiscal Year: 2004
    ..leuprolide acetate (Lupron), a gonadotropin releasing hormone (GnRH) agonist; 2) Antide, a GnRH antagonist; 3) levonorgestrel (Norplant), a progestogen implant; and 4) altrenogest (Regumate), an oral progestogen...
  16. NORPLANT USE BY LOW-INCOME WOMEN
    Leslie Clarke; Fiscal Year: 1993
    ..This study responds to the need for research on new contraceptive methods and the need for reductions in unintended pregnancies in the U.S. as set forth in Healthy People 2000. ..
  17. UNDERSTANDING OVARIAN CONTROL IN RARE BIOMEDICAL MODELS
    KATHARINE PELICAN; Fiscal Year: 2002
    ..leuprolide acetate (Lupron), a gonadotropin releasing hormone (GnRH) agonist; 2) Antide, a GnRH antagonist; 3) levonorgestrel (Norplant), a progestogen implant; and 4) altrenogest (Regumate), an oral progestogen...
  18. UNDERSTANDING OVARIAN CONTROL IN RARE BIOMEDICAL MODELS
    KATHARINE PELICAN; Fiscal Year: 2005
    ..leuprolide acetate (Lupron), a gonadotropin releasing hormone (GnRH) agonist; 2) Antide, a GnRH antagonist; 3) levonorgestrel (Norplant), a progestogen implant; and 4) altrenogest (Regumate), an oral progestogen...
  19. UNDERSTANDING OVARIAN CONTROL IN RARE BIOMEDICAL MODELS
    KATHARINE PELICAN; Fiscal Year: 2006
    ..leuprolide acetate (Lupron), a gonadotropin releasing hormone (GnRH) agonist; 2) Antide, a GnRH antagonist; 3) levonorgestrel (Norplant), a progestogen implant; and 4) altrenogest (Regumate), an oral progestogen...
  20. UNDERSTANDING OVARIAN CONTROL IN RARE BIOMEDICAL MODELS
    KATHARINE PELICAN; Fiscal Year: 2003
    ..leuprolide acetate (Lupron), a gonadotropin releasing hormone (GnRH) agonist; 2) Antide, a GnRH antagonist; 3) levonorgestrel (Norplant), a progestogen implant; and 4) altrenogest (Regumate), an oral progestogen...
  21. REPRODUCTIVE PARAMETERS OF CHIMPANZEE MODEL
    Kenneth Gould; Fiscal Year: 2000
    ..G. Use of IUDs as a management tool for the chimpanzee (Pan troglodytes). J. Med. Primatol. (In press). P51RR00165-38 1/1/98 - 12/31/98 Yerkes Regional Primate Research Center ..
  22. Obesity Prevention Tailored for Health II
    Kim Reynolds; Fiscal Year: 2009
    ..Two 24-hour recalls will be completed at each assessment period. BMI and physical activity will be objectively measured through height and weight assessments, and through the use of accelerometry to assess physical activity. ..
  23. Obesity Prevention Tailored for Health II
    KIM DANIEL REYNOLDS; Fiscal Year: 2010
    ..Two 24-hour recalls will be completed at each assessment period. BMI and physical activity will be objectively measured through height and weight assessments, and through the use of accelerometry to assess physical activity. ..
  24. Suppression of Breakthrough Bleeding in LNG-IUS Users
    Robert Brenner; Fiscal Year: 2003
    The Mirena(c) (Leiras, OY, Finland) is an intrauterine system (IUS) that releases levonorgestrel (LNG) and provides women with highly effective contraception for 5 years...
  25. Mifepristone for Prevention of Breakthrough Bleeding
    John Jain; Fiscal Year: 2003
    ..Mifepristone has been shown to decrease breakthrough bleeding in women using levonorgestrel implants...
  26. Suppression of Breakthrough Bleeding in LNG-IUS Users
    Ov Slayden; Fiscal Year: 2005
    The Mirena(c) (Leiras, OY, Finland) is an intrauterine system (IUS) that releases levonorgestrel (LNG) and provides women with highly effective contraception for 5 years...
  27. Suppression of Breakthrough Bleeding in LNG-IUS Users
    Robert Brenner; Fiscal Year: 2004
    The Mirena(c) (Leiras, OY, Finland) is an intrauterine system (IUS) that releases levonorgestrel (LNG) and provides women with highly effective contraception for 5 years...
  28. Suppression of Breakthrough Bleeding in LNG-IUS Users
    Ov Slayden; Fiscal Year: 2006
    ..provided by applicant): The Mirena(c) (Leiras, OY, Finland) is an intrauterine system (IUS) that releases levonorgestrel (LNG) and provides women with highly effective contraception for 5 years...
  29. Suppression of Breakthrough Bleeding in LNG-IUS Users
    Robert Brenner; Fiscal Year: 2002
    The Mirena(c) (Leiras, OY, Finland) is an intrauterine system (IUS) that releases levonorgestrel (LNG) and provides women with highly effective contraception for 5 years...
  30. Mifepristone for Prevention of Breakthrough Bleeding
    John Jain; Fiscal Year: 2002
    ..Mifepristone has been shown to decrease breakthrough bleeding in women using levonorgestrel implants...
  31. Mifepristone for Prevention of Breakthrough Bleeding
    John Jain; Fiscal Year: 2004
    ..Mifepristone has been shown to decrease breakthrough bleeding in women using levonorgestrel implants...
  32. Progestin Effects on Uterine Hemostasis & Angiogenesis
    Charles Lockwood; Fiscal Year: 2006
    ..abstract_text> ..
  33. Cooperative Contraceptive Research Center
    Regine Sitruk Ware; Fiscal Year: 2005
    ..II) A vaginal gel containing both the microbicide Carraguard and the contraceptive steroid levonorgestrel (CARRA/LNG) will be tested for dual-protection against sexually transmitted infections and conception...
  34. Cooperative Contraceptive Research Center
    Regine Sitruk Ware; Fiscal Year: 2004
    ..II) A vaginal gel containing both the microbicide Carraguard and the contraceptive steroid levonorgestrel (CARRA/LNG) will be tested for dual-protection against sexually transmitted infections and conception...
  35. Cooperative Contraceptive Research Center
    Regine Sitruk Ware; Fiscal Year: 2003
    ..II) A vaginal gel containing both the microbicide Carraguard and the contraceptive steroid levonorgestrel (CARRA/LNG) will be tested for dual-protection against sexually transmitted infections and conception...
  36. Cooperative Contraceptive Research Center
    Regine Sitruk Ware; Fiscal Year: 2006
    ..II) A vaginal gel containing both the microbicide Carraguard and the contraceptive steroid levonorgestrel (CARRA/LNG) will be tested for dual-protection against sexually transmitted infections and conception...
  37. Cooperative Contraceptive Research Center
    Regine Sitruk Ware; Fiscal Year: 2002
    ..II) A vaginal gel containing both the microbicide Carraguard and the contraceptive steroid levonorgestrel (CARRA/LNG) will be tested for dual-protection against sexually transmitted infections and conception...
  38. Cooporative Contraceptive Research Center
    Regine Sitruk Ware; Fiscal Year: 2009
    ..for men and women: 1) A vaginal gel containing the microbicide Carraguard(TM) and the contraceptive steroid levonorgestrel (CARRA/LNG) will be further tested for dual protection against sexually transmitted infections and conception...
  39. Cooporative Contraceptive Research Center
    Regine Sitruk Ware; Fiscal Year: 2009
    ..for men and women: 1) A vaginal gel containing the microbicide Carraguard(TM) and the contraceptive steroid levonorgestrel (CARRA/LNG) will be further tested for dual protection against sexually transmitted infections and conception...
  40. Cooporative Contraceptive Research Center
    Regine Sitruk Ware; Fiscal Year: 2009
    ..for men and women: 1) A vaginal gel containing the microbicide Carraguard(TM) and the contraceptive steroid levonorgestrel (CARRA/LNG) will be further tested for dual protection against sexually transmitted infections and conception...
  41. Cooporative Contraceptive Research Center
    REGINE SITRUK WARE; Fiscal Year: 2010
    ..for men and women: 1) A vaginal gel containing the microbicide Carraguard(TM) and the contraceptive steroid levonorgestrel (CARRA/LNG) will be further tested for dual protection against sexually transmitted infections and conception...
  42. Carraguard/Levonogestrel Combination for Dual Protection
    REGINE SITRUK WARE; Fiscal Year: 2011
    ..the main ingredient of which is the sulfated polysaccharide carrageenan) with the synthetic progestin levonorgestrel (LNg)...
  43. Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia
    Laura C Hanson; Fiscal Year: 2012
    ..The trial will enroll 300 surrogate decision-makers for advanced dementia patients from 20 nursing homes. ..
  44. Conspiracies, Perceived Discrimination & Sexual Behavior
    Sheryl Thorburn; Fiscal Year: 2002
    ..Findings from this study will inform efforts to prevent HIV and other STDs, as well as unintended pregnancy, among African Americans nationally. ..
  45. ORAL CONTRACEPTIVES FOR DYSMENORRHEA IN ADOLESCENT GIRLS
    Anne Davis; Fiscal Year: 2001
    ..1 milligrams levonorgestrel or a placebo...
  46. CONTROLLED RELEASE OF ATRIAL NATRIURETIC FACTOR
    Maria Rupnick; Fiscal Year: 1999
    ..End of Abstract) ..
  47. CONTROLLED RELEASE OF ATRIAL NATRIURETIC FACTOR
    Maria Rupnick; Fiscal Year: 2001
    ..End of Abstract) ..
  48. Enhancing Childrens' and Parents' Asthma Management
    Sharon Horner; Fiscal Year: 2004
    ..Follow-up data will be collected 4 months (Time 3) and 8 months (Time 4) later and analyzed. ..
  49. Enhancing Childrens' and Parents' Asthma Management
    Sharon Horner; Fiscal Year: 2006
    ..Follow-up data will be collected 4 months (Time 3) and 8 months (Time 4) later and analyzed. ..
  50. Enhancing Childrens' and Parents' Asthma Management
    Sharon Horner; Fiscal Year: 2005
    ..Follow-up data will be collected 4 months (Time 3) and 8 months (Time 4) later and analyzed. ..
  51. Enhancing Childrens' and Parents' Asthma Management
    Sharon Horner; Fiscal Year: 2003
    ..Follow-up data will be collected 4 months (Time 3) and 8 months (Time 4) later and analyzed. ..
  52. CARRAGUARD-LEVONORGESTREL COMBINATION -- DUAL PROTECTION
    Regine Sitruk Ware; Fiscal Year: 2002
    ..the microbicide Carraguard, which is the sulfated polysaccharide, carrageenan, with the synthetic progestin, levonorgestrel (LNG)...
  53. DECISIONS CONCERNING NORPLANT USE AND DISCONTINUATION
    Andrew Davidson; Fiscal Year: 1992
    ....
  54. Piloting a Mobile App for HIV Risk Reduction among Young Latinas &Black Females
    SONIA K GONZALEZ; Fiscal Year: 2012
    ....
  55. ADOLESCENT MISCONCEPTIONS ABOUT HORMONAL CONTRACEPTION
    LIANA CLARK; Fiscal Year: 2003
    ..Increased usage and improved compliance with Depo-Provera, Norplant and the oral contraceptive pill will result in an overall decrease in the rate of unintended adolescent pregnancy. ..
  56. ADOLESCENT MISCONCEPTIONS ABOUT HORMONAL CONTRACEPTION
    LIANA CLARK; Fiscal Year: 1999
    ..Increased usage and improved compliance with Depo-Provera, Norplant and the oral contraceptive pill will result in an overall decrease in the rate of unintended adolescent pregnancy. ..
  57. ADOLESCENT MISCONCEPTIONS ABOUT HORMONAL CONTRACEPTION
    LIANA CLARK; Fiscal Year: 2000
    ..Increased usage and improved compliance with Depo-Provera, Norplant and the oral contraceptive pill will result in an overall decrease in the rate of unintended adolescent pregnancy. ..
  58. ADOLESCENT MISCONCEPTIONS ABOUT HORMONAL CONTRACEPTION
    LIANA CLARK; Fiscal Year: 2001
    ..Increased usage and improved compliance with Depo-Provera, Norplant and the oral contraceptive pill will result in an overall decrease in the rate of unintended adolescent pregnancy. ..
  59. ADOLESCENT MISCONCEPTIONS ABOUT HORMONAL CONTRACEPTION
    LIANA CLARK; Fiscal Year: 2002
    ..Increased usage and improved compliance with Depo-Provera, Norplant and the oral contraceptive pill will result in an overall decrease in the rate of unintended adolescent pregnancy. ..
  60. PROGESTERONE IMPLANTS ENHANCE SIV VAGINAL TRANSMISSION & EARLY VIRUS LOAD
    Ronald Veazey; Fiscal Year: 2001
    ..progestin Publication Hild-Petito S, Veazey RS, Larner JM, Reel JR, Blye RP Effects of two progestin-only contraceptives, Depo-Provera and Norplant-II on the vaginal epithelium of rhesus monkeys AIDS Res Hum Retro, 14:S1:S125-S130, 1998 ..
  61. PROGESTERONE IMPLANTS ENHANCE SIV VAGINAL TRANSMISSION & EARLY VIRUS LOAD
    Ronald Veazey; Fiscal Year: 1999
    ..progestin Publication Hild-Petito S, Veazey RS, Larner JM, Reel JR, Blye RP Effects of two progestin-only contraceptives, Depo-Provera and Norplant-II on the vaginal epithelium of rhesus monkeys AIDS Res Hum Retro, 14:S1:S125-S130, 1998 ..
  62. St. John's Wort Effects on Levonorgestrel
    Patricia Murphy; Fiscal Year: 2005
    ..John's Wort (Hypericum perforatum), on metabolism of levonorgestrel in a dosing regimen for emergency contraception...
  63. St. John's Wort Effects on Levonorgestrel
    Patricia Murphy; Fiscal Year: 2006
    ..John's Wort (Hypericum perforatum), on metabolism of levonorgestrel in a dosing regimen for emergency contraception...
  64. PROGESTERONE IMPLANTS ENHANCE SIV VAGINAL TRANSMISSION & EARLY VIRUS LOAD
    Ronald Veazey; Fiscal Year: 2002
    ..progestin Publication Hild-Petito S, Veazey RS, Larner JM, Reel JR, Blye RP Effects of two progestin-only contraceptives, Depo-Provera and Norplant-II on the vaginal epithelium of rhesus monkeys AIDS Res Hum Retro, 14:S1:S125-S130, 1998 ..
  65. CLINICAL EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
    Jeffrey Jensen; Fiscal Year: 2011
    ..A new long acting formulation of Levonorgestrel Butanoate (LB), delivered by injection, has been developed...
  66. Conspiracies, Perceived Discrimination & Sexual Behavior
    Sheryl Thorburn; Fiscal Year: 2003
    ..Findings from this study will inform efforts to prevent HIV and other STDs, as well as unintended pregnancy, among African Americans nationally. ..
  67. Web Based Intervention for African American Mothers
    Diane Brage Hudson; Fiscal Year: 2005
    ..Subjects will be randomly assigned to the Experimental Group and the Control Group. Descriptive summary statistics, repeated measures analysis of co-variance, and reliability indices will be used to test the study aims. ..
  68. BIODEGRADABLE LEVONORGESTREL CONTRACEPTIVE IMPLANTS
    Larry Nichols; Fiscal Year: 2000
    b>Levonorgestrel is a steroid widely used for fertility regulation...
  69. Clinical Translational Research in Transplant Nephrology
    Bryan Becker; Fiscal Year: 2006
    ..It will also work to meet the NIH's goal of increasing the number of physician-scientists conducting high-quality patient-oriented research. ..
  70. NORPLANT ADOPTION AND DISCONTINUATION IN THE U.S.
    Koray Tanfer; Fiscal Year: 1992
    ..At the end of each project year, the results will be disseminated through reports, working papers, presentations at professional meetings; and a final monograph will synthesize the results from all phases of the proposed research...
  71. CONTROLLED RELEASE OF ATRIAL NATRIURETIC FACTOR
    Maria Rupnick; Fiscal Year: 2000
    ..End of Abstract) ..